ライフサイエンスコーパス: second malignancy

1 deaths occurred (six disease-related and one second malignancy).

2 S relapses), four residual lymphoma, and two second malignancies).

3 rred among 135 patients (12 relapses and two second malignancies).

4 ed with leukemia relapse or development of a second malignancy.

5 risk of leukemia relapse or development of a second malignancy.

6 ful, but patients have a significant risk of second malignancy.

7 er, there is a small but significant risk of second malignancy.

8 whether the cause is recurrent disease or a second malignancy.

9 and are, therefore, at risk of developing a second malignancy.

10 herapy, recurrence, time since diagnosis, or second malignancy.

11 g in CR for 14, 21, and 71 weeks, all from a second malignancy.

12 lung cancer (NSCLC) are at higher risk of a second malignancy.

13 tive impairment, endocrinopathy, and risk of second malignancy.

14 entire cohort, 9.6% of patients have died of second malignancy.

15 pproaching 21% at 10 years from diagnosis of second malignancy.

16 rker for, the induction of a therapy-induced second malignancy.

17 and who were examined for the induction of a second malignancy.

18 potential mechanism for doxorubicin-related second malignancies.

19 apy did not significantly affect the risk of second malignancies.

20 termine whether they had true recurrences or second malignancies.

21 Five other patients died from other second malignancies.

22 s is effective and safe, with no increase in second malignancies.

23 no increase in late adverse events, namely, second malignancies.

24 the association between multiple myeloma and second malignancies.

25 llow-up, and limitations of ascertainment of second malignancies.

26 tiologic clues to lymphoma as well as to the second malignancies.

27 s of follow-up, and reporting AML/MDS or all second malignancies.

28 D and was not associated with an increase in second malignancies.

29 eritable predisposition are at high risk for second malignancies.

30 There were seven second malignancies.

31 ut also to reduce the risk of development of second malignancies.

32 t of multi-factorial diseases, in particular second malignancies.

33 Forty-seven patients developed 58 second malignancies.

34 incidence ratios showed excess risk for all second malignancies (12; 95% confidence interval [CI], 8

35 -1.6% for Hodgkin's disease, 8.1%+/-2.6% for second malignancy, 4.0%+/-1.8% for cardiac disease, 3.9%

36 ncies differ and whether the occurrence of a second malignancy affects the risk of subsequent maligna

37 to reduce the incidence of radiation-induced second malignancies after a course of definitive radiati

38 w-up demonstrates a significant incidence of second malignancies after ABMT for NHL.

39 The overall risk of second malignancies after Ewing's sarcomas is similar to

40 review discusses current knowledge regarding second malignancies after multiple myeloma and gives fut

41 evious studies have shown increased risks of second malignancies after non-Hodgkin's lymphoma (NHL) a

42 The excess risk of second malignancy after Hodgkin disease continues to be

43 The excess risk of second malignancy after Hodgkin disease is an increasing

44 e at treatment has a major effect on risk of second malignancy after Hodgkin's disease.

45 mine the prognosis of patients who develop a second malignancy after radiation treatment with or with

46 ith clinical stage I-IV Hodgkin disease, 181 second malignancies and 18 third malignancies were obser

47 cancer treatment, and may raise the risk of second malignancies and comorbidities.

48 a mechanistic paradigm for the induction of second malignancies and drug resistance.

49 ow-up, presents data on failure patterns and second malignancies and explores selected subset analyse

50 phohematopoietic and non-lymphohematopoietic second malignancies and no secondary malignancies of the

51 er, the leading causes of excess deaths were second malignancies and recurrent disease, followed by i

52 New information relating to the risk of second malignancies and the ability of the myeloid growt

53 sts to advise patients regarding the risk of second malignancies and treatment-related cancers.

54 w-up of 22.6 years, 832 patients developed a second malignancy and 126 patients a third one.

55 mulative incidence rates at 20 years for any second malignancy and for secondary sarcoma were 9.2% (S

56 rough 1993 was assembled and followed-up for second malignancy and mortality.

57 reatment, including the risk of developing a second malignancy and non-neoplastic complications, most

58 e events, including 90 leukemic relapses, 40 second malignancies, and four deaths in remission.

59 ffects like osteoporosis, heart disease, and second malignancies, and promoting healthy lifestyles.

60 Toxicities, including second malignancies, appear acceptable, given the magnit

61 Because second malignancies are associated with high mortality,

62 city, marrow toxicity, or the development of second malignancies are of lesser importance given that

63 Second malignancies are responsible for a significant fr

64 ality, locoregional and distant failure, and second malignancies as first events.

65 ribes associations between sporadic GIST and second malignancies, as well as new contributions to our

66 There have been 18 second malignancies associated with ABVD and 28 associat

67 We aimed to quantify risks of second malignancies associated with RAI treatment for DT

68 The cumulative risk of developing second malignancies at 10 years was 0.9%, 6.6%, and 6% w

69 The cumulative incidence of second malignancies at 7 years was 5.5% (95% CI, 4.0 to

70 The estimated cumulative risk of a second malignancy at 20 years after diagnosis was 1.8% (

71 tients were alive and no patient developed a second malignancy at a median follow up of 25 months.

72 17.2 years) and the cumulative incidence of second malignancy before another first event was 2.7% (9

73 Two patients developed second malignancies, but none have developed myelodyspla

74 uce cardiac complications but did not lessen second malignancies compared with higher doses used hist

75 able, but was associated with a high rate of second malignancies compared with historical controls.

76 A total of 48 patients (10.2%) developed a second malignancy during follow-up (non-Hodgkin lymphoma

77 A second malignancy during the course of follow-up was dia

78 Of 11 second malignancies, eight occurred in patients who rece

79 Of seven patients with second malignancies, five died.

80 maximize survival and minimize the risk for second malignancies for individual patients.

81 free of a second malignancy, patients with a second malignancy had a higher risk of developing subseq

82 An excess risk of second malignancies has been reported in survivors of Ew

83 Five second malignancies have occurred in four patients.

84 hat Hodgkin lymphoma survivors who develop a second malignancy have increased risk of developing yet

85 e of Hodgkin's disease increased the risk of second malignancy (hazards ratio [HR] = 2.6, P < .001).

86 adverse treatment effects (treatment death, second malignancy; HR 0.52, 0.24-1.11, p=0.11).

87 of death resulting from noncancer causes and second malignancies (ie, competing mortality).

88 There seems to be no increased risk of second malignancies in patients undergoing LRT using mod

89 ng to evaluate the possible clonal origin of second malignancies in various cancer types.

90 Second malignancies in women diagnosed with thyroid canc

91 ecurrent primary malignancy in 61% of cases, second malignancy in 20%, nonneoplastic treatment compli

92 Second malignancies included renal cell carcinoma (RCC;

93 Six patients were diagnosed with second malignancies, including four patients who develop

94 ra (P < .0001), while the risk of death from second malignancies increased, although not statisticall

95 with high mortality, prognostic factors for second malignancy influence long-term overall survival.

96 nical studies have shown that development of second malignancies is an uncommon but real risk for cho

97 ing risk found that the 10-year incidence of second malignancy is 21%, with 10.0% non-MDS malignancie

98 The principal risk factor for second malignancy is increased age at ABMT (P = .0002).

99 te consequences such as an increased risk of second malignancy may compromise this approach and close

100 ed as progression, malignant transformation, second malignancy, medical complication, or external cau

101 No patients developed a second malignancy, metastatic disease, renal disease, or

102 deaths were NLPHL related (n = 10), whereas second malignancies (n = 20) and nonmalignant conditions

103 ents resulted from Hodgkin's disease (n=36), second malignancies (n=14), infections (n=7), accidents

104 nts, including relapse/progression (n = 35), second malignancy (n = 2), and accidental death (n = 1);

105 use of higher mortality rates resulting from second malignancies observed after treatment with BEACOP

106 term complications such as radiation-induced second malignancies occur in a subset of patients follow

107 Second malignancies occurred in 459 cohort members.

108 Four of the five second malignancies occurred in children younger than 2

109 Three hundred twenty-two second malignancies occurred.

110 No second malignancies occurred.

111 In total, 123 second malignancies occurred.

112 onizing radiation in 12 radiation-associated second malignancies of different tumour types.

113 as associated with an increased incidence of second malignancies, often comprising hematological canc

114 s not been a markedly increased incidence of second malignancies or late opportunistic infections.

115 red for events, defined as tumor recurrence, second malignancy, or death.

116 event-free survival (events: relapse, death, second malignancy, or failure to achieve complete remiss

117 Recurrent disease, second malignancy, or late-onset treatment effects in an

118 = 25) or surgery, had a coexistent or prior second malignancy, or who had unresectable or metastatic

119 investigate frequency and characteristics of second malignancies (other than acute myeloid leukemia,

120 Cancer survivors are at greater risk for second malignancies, other comorbidities, and accelerate

121 patients are at elevated risk of developing second malignancy, particularly leukemia and lung cancer

122 Compared with patients still free of a second malignancy, patients with a second malignancy had

123 rs, there was a 2.3% and 4.0% excess risk of second malignancy per person per year.

124 gkin's disease was associated with risk of a second malignancy related to treatment, the literature i

125 phoma subtypes contribute to the patterns of second malignancy risk.

126 Nine died of progressive disease (one second malignancy), six relapsed and are alive with dise

127 ios (RR) were calculated to compare observed second malignancy (SM) rates in this cohort with expecte

128 Late mortality, second malignancy (SMN) rates, health care utilization,

129 thelioma may need to be added to the list of second malignancies that arise following radiation thera

130 h chemotherapy alone leads to raised risk of second malignancy, this risk is lower and affects fewer

131 r survivorship due to many late effects (eg, second malignancies, thyroid disease, cardiovascular dis

132 In HL survivors who had a second malignancy, treating physicians should be aware o

133 a CNS relapse; 16 secondary AML; three other second malignancies; two withdrew for transplant; three

134 The observed-to-expected ratio for second malignancies was 2.03 (95% confidence interval, 1

135 No increase in second malignancies was noted with ixazomib therapy (12

136 urrent information on relapse of disease and second malignancies was obtained via an institutional re

137 The frequency of second malignancies was similar between the two treatmen

138 he incidence of opportunistic infections and second malignancies was similar in both groups.

139 The cumulative incidence of any second malignancy was 10.6% at 20 years, increasing to 2

140 Duration from diagnosis of initial tumor to second malignancy was 33, 35, 57, 66, and 92 months.

141 The 5-year survival after development of a second malignancy was 38.1%, with the worst prognosis se

142 The risk of a second malignancy was 4.7-fold increased (95% confidence

143 ion; the risk for a third malignancy after a second malignancy was 5.4-fold (95% CI, 4.4-6.5) increas

144 The relative risk (RR) of developing a second malignancy was 5.6.

145 per 10,000 person-years (AR) of developing a second malignancy was 69.6 (7.0% excess risk per person

146 Time to second malignancy was 7 years 8 months, 4 years 9 months

147 The median latency to the diagnosis of the second malignancy was 7.6 years (range, 3.5 to 25.7).

148 estigation were observed, and occurrences of second malignancy was compared with expectations based o

149 Their risk of leukemia relapse or second malignancy was compared with that of survivors wh

150 The 15-year risk of any second malignancy was nearly identical for both cohorts

151 Survival following development of a second malignancy was poor in patients with leukemia, ga

152 The median interval to diagnosis of a second malignancy was shortest for leukemia, 4.3 years,

153 tuarial risks, and absolute excess risks for second malignancies were calculated.

154 Cumulative incidence rates of second malignancies were calculated.

155 Second malignancies were categorized as contralateral br

156 and cumulative radiation dose to the risk of second malignancies were evaluated.

157 None of the second malignancies were non-Hodgkin's lymphoma (NHL).

158 Second malignancies were observed in 18 MPT-T patients v

159 Second malignancies were observed in 21 patients with ra

160 Nine second malignancies were observed with thalidomide-predn

161 Overall, 23 second malignancies were registered during follow-up: fo

162 relapses involved the bone marrow, and three second malignancies were reported.

163 Overall, 13 second malignancies were reported: one in the ABVD arm a

164 Second malignancies were significantly more frequent in

165 Fertility was not greatly impaired, and second malignancies were uncommon.

166 lative risk (RR) and absolute excess risk of second malignancy were 4.6 and 89.3/10 000 person-years.

167 profile, and without increasing the risk of second malignancies, whereas adding veliparib did not im

168 ange, 3.0 to 30), 16 patients have developed second malignancies, which included 10 sarcomas (five os

169 Second malignancies, which might be attributed to treatm

170 ot associated with a significant increase in second malignancies with this doxorubicin-containing che

171 Five of the 198 children developed second malignancies, with a cumulative risk at 8 years o